Press Releases Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Real-time Estimate Cboe BZX Other stock markets 09:35:48 2024-06-10 am EDT			5-day change	1st Jan Change
101.8 ^USD	-1.45%		-2.10%	+12.03%

Jun. 07	Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing	MT
Jun. 05	Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)	May. 30	PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 06	PR
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance	May. 03	AQ
Blueprint Medicines: Q1 Earnings Snapshot	May. 02	AQ
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	Apr. 18	PR
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	Apr. 11	PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 04	PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 06	PR
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 26	AQ
Blueprint Medicines: Q4 Earnings Snapshot	Feb. 15	AQ
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 05	PR
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024	Feb. 01	PR
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 05	PR
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference	Dec. 18	PR
EC approves treatment for rare haematological disorder	Dec. 13	AQ
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis	Dec. 12	PR
EUCOPE Member Spotlight, Q&A with Blueprint Medicines	Dec. 12	AQ
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 04	PR
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit	Nov. 28	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Press Releases

Filters